Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | RET |
Variant | D567Y |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | RET D567Y lies within the extracellular domain of the Ret protein (UniProt.org). D567Y results in increased phosphorylation of Ret and Erk, IL3-independent growth in culture, and tumor formation in a mouse model (PMID: 36166639). |
Associated Drug Resistance | |
Category Variants Paths |
RET mutant RET act mut RET D567Y |
Transcript | NM_020975.6 |
gDNA | chr10:g.43112903G>T |
cDNA | c.1699G>T |
Protein | p.D567Y |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406744.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406763.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020630.7 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406765.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020975.5 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406743.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020975.6 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_020630.5 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406759.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
NM_001406760.1 | chr10:g.43112903G>T | c.1699G>T | p.D567Y | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET D567Y | Advanced Solid Tumor | sensitive | Selpercatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Retevmo (selpercatinib) inhibited Ret signaling and viability in transformed cells expressing RET D567Y in culture and inhibited tumor growth in a cell line xenograft model (PMID: 36166639). | 36166639 |
RET D567Y | Advanced Solid Tumor | sensitive | Pralsetinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Gavreto (pralsetinib) inhibited Ret signaling and viability in transformed cells expressing RET D567Y in culture and inhibited tumor growth in a cell line xenograft model (PMID: 36166639). | 36166639 |